Arsenic trioxide suppresses cell growth and migration via inhibition of miR-27a in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 469, Issue 1, 2016, Pages 55-61

  Zhang, Shunhua ^a   Ma, Cong ^a   Pang, Haijie ^a   Zeng, Fanpeng ^a   Cheng, Long ^a   Fang, Binbin ^a   Ma, Jia ^a   Shi, Ying ^a   Hong, Haiyu ^b   Chen, Jianyan ^c   Wang, Zhiwei ^a,d   Xia, Jun ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Breast cancer; Cell growth; miR 27a

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN E; FBW7 PROTEIN; MICRORNA; MICRORNA 27A; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN27 MICRORNA, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MOTILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; MTT ASSAY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; OXIDES; TREATMENT OUTCOME;

EID: 84950293824     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.11.071     Document Type: Article

References (37)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA A Cancer J. Clin. 65 2015 5 29
2. C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, and A. Jemal Cancer treatment and survivorship statistics, 2014 CA a cancer J. Clin. 64 2014 252 271
3. C. DeSantis, J. Ma, L. Bryan, and A. Jemal Breast cancer statistics, 2013 CA a cancer J. Clin. 64 2014 52 62
4. H.P. Kourea, V. Zolota, and C.D. Scopa Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions Curr. Mol. Pharmacol. 7 2014 4 21
5. A. Dittrich, H. Gautrey, D. Browell, and A. Tyson-Capper The HER2 signaling network in breast cancer-like a spider in its web J. Mammary Gl. Biol. Neoplasia 19 2014 253 270
6. D. Zardavas, A. Irrthum, C. Swanton, and M. Piccart Clinical management of breast cancer heterogeneity Nat. Rev. Clin. Oncol. 12 2015 381 394
7. E. Lengfelder, W.K. Hofmann, and D. Nowak Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions Expert Rev. Anticancer Ther. 13 2013 1035 1043
8. J. Zhou Arsenic trioxide: an ancient drug revived Chin. Med. J. 125 2012 3556 3560
9. R.C. Sun, P.G. Board, and A.C. Blackburn Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells Mol. cancer 10 2011 142
10. X. Wang, P. Gao, M. Long, F. Lin, J.X. Wei, J.H. Ren, L. Yan, T. He, Y. Han, and H.Z. Zhang Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide Med. Oncol. 28 2011 1225 1254
11. W. Liu, Y. Gong, H. Li, G. Jiang, S. Zhan, H. Liu, and Y. Wu Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkappaB kinase beta expression and localization Cancer Biother. Radiopharm. 27 2012 504 512
12. W. Zhang, L. Wang, Q. Fan, X. Wu, F. Wang, R. Wang, Z. Ma, J. Yang, and S.H. Lu Arsenic trioxide re-sensitizes ERalpha-negative breast cancer cells to endocrine therapy by restoring ERalpha expression in vitro and in vivo Oncol. Rep. 26 2011 621 628
13. C. Guilbert, M.G. Annis, Z. Dong, P.M. Siegel, W.H. Miller Jr., and K.K. Mann Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer PloS One 8 2013 e85995
14. A.L. Kasinski, and F.J. Slack Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nat. Rev. Cancer 11 2011 849 864
15. G.A. Calin, and C.M. Croce MicroRNA signatures in human cancers Nat. Rev. Cancer 6 2006 857 866
16. M. van Kouwenhove, M. Kedde, and R. Agami MicroRNA regulation by RNA-binding proteins and its implications for cancer Nat. Rev. Cancer 11 2011 644 656
17. W. Tang, J. Zhu, S. Su, W. Wu, Q. Liu, F. Su, and F. Yu MiR-27 as a prognostic marker for breast cancer progression and patient survival PloS One 7 2012 e51702
18. W. Tang, F. Yu, H. Yao, X. Cui, Y. Jiao, L. Lin, J. Chen, D. Yin, E. Song, and Q. Liu miR-27a regulates endothelial differentiation of breast cancer stem like cells Oncogene 33 2014 2629 2638
19. J. Ma, B. Fang, F. Zeng, C. Ma, H. Pang, L. Cheng, Y. Shi, H. Wang, B. Yin, J. Xia, and Z. Wang Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Oncotarget 6 2015 1740 1749
20. J. Xia, Q. Duan, A. Ahmad, B. Bao, S. Banerjee, Y. Shi, J. Ma, J. Geng, Z. Chen, K.M. Rahman, L. Miele, F.H. Sarkar, and Z. Wang Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells Curr. Drug Targets 13 2012 1750 1756
21. J. Ma, L. Cheng, H. Liu, J. Zhang, Y. Shi, F. Zeng, L. Miele, F.H. Sarkar, J. Xia, and Z. Wang Genistein down-regulates miR-223 expression in pancreatic cancer cells Curr. drug targets 14 2013 1150 1156
22. Q. Yang, Y. Wang, X. Lu, Z. Zhao, L. Zhu, S. Chen, Q. Wu, C. Chen, and Z. Wang MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells Oncotarget 6 2015 3268 3279
23. Y. Cao, S.L. Yu, Y. Wang, G.Y. Guo, Q. Ding, and R.H. An MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24 Tumour Biol. 32 2011 179 188
24. Y. Zhang, J.H. Wu, F. Han, J.M. Huang, S.Y. Shi, R.D. Gu, X.L. Chen, and B. He Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a Neoplasma 60 2013 247 253
25. S. Chen, L. Zhu, J. Huang, Y. Cai, X. Lu, Q. Yang, Q. Wu, C. Chen, and Z. Wang Arsenic trioxide targets miR-125b in glioma cells Curr. Pharm. Des. 20 2014 5354 5361
26. X. Wang, F. Jiang, J. Mu, X. Ye, L. Si, S. Ning, Z. Li, and Y. Li Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491 Toxicol. Lett. 227 2014 75 83
27. Y. Wang, L. Wang, C. Yin, B. An, Y. Hao, T. Wei, L. Li, and G. Song Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells Mol. Med. Rep. 12 2015 1233 1238
28. L. Si, F. Jiang, Y. Li, X. Ye, J. Mu, X. Wang, S. Ning, C. Hu, and Z. Li Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells Mol. Carcinog. 54 2015 859 869
29. Y.Q. Ren, F. Fu, and J. Han MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27 Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 21 2015 1297 1303
30. P. Gasparini, L. Cascione, M. Fassan, F. Lovat, G. Guler, S. Balci, C. Irkkan, C. Morrison, C.M. Croce, C.L. Shapiro, and K. Huebner microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers Oncotarget 5 2014 1174 1184
31. L. Xu, J. Xiang, J. Shen, X. Zou, S. Zhai, Y. Yin, P. Li, X. Wang, and Q. Sun Oncogenic microRNA-27a is a target for genistein in ovarian cancer cells Anti-cancer Agents Med. Chem. 13 2013 1126 1132
32. J. Ma, B. Fang, F. Zeng, H. Pang, C. Ma, and J. Xia Grape seed proanthocyanidins extract inhibits pancreatic cancer cell growth through down-regulation of miR-27a expression J. Central South Univ. Med. Sci. 40 2015 46 52
33. N. Banerjee, S. Talcott, S. Safe, and S.U. Mertens-Talcott Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation Breast Cancer Res. Treat. 136 2012 21 34
34. M. Lerner, J. Lundgren, S. Akhoondi, A. Jahn, H.F. Ng, F. Akbari Moqadam, J.A. Oude Vrielink, R. Agami, M.L. Den Boer, D. Grander, and O. Sangfelt MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression Cell Cycle 10 2011 2172 2183
35. C. Spruck miR-27a regulation of SCF(Fbw7) in cell division control and cancer Cell Cycle 10 2011 3232 3233
36. Q. Wang, D.C. Li, Z.F. Li, C.X. Liu, Y.M. Xiao, B. Zhang, X.D. Li, J. Zhao, L.P. Chen, X.M. Xing, S.F. Tang, Y.C. Lin, Y.D. Lai, P. Yang, J.L. Zeng, Q. Xiao, X.W. Zeng, Z.N. Lin, Z.X. Zhuang, S.M. Zhuang, and W. Chen Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen Oncogene 30 2011 3875 3886
37. L. Wang, X. Ye, Y. Liu, W. Wei, and Z. Wang Aberrant regulation of FBW7 in cancer Oncotarget 5 2014 2000 2015